• Ambu’s 2025/26 annual report showed endoscopy driving growth, with rising adoption of single-use devices across its markets.
• Respiratory growth accelerated as the SureSight video laryngoscope rollout gained traction; urology, ENT and gastrointestinal applications maintained momentum.
• Anesthesia weakened as prior price increases reduced volumes at selected US accounts; patient monitoring grew.
• The September 2026 acquisition of TIMS Medical expanded reporting capabilities, adding access to around 7,000 US hospital installations.
• Accelerated investment in upcoming product launches replaced the interim 2027/28 margin objective with annual earnings growth exceeding organic revenue growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ambu A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.